BriaCell Bria-ABC Phase 3 First Blinded Readouts at ASCO 2026: Sustained Quality of Life and Time Without Symptoms in Heavily Pretreated Metastatic Breast Cancer
BriaCell's three June 1 poster presentations moved past the previously reported 16.6-month Phase 2 median overall survival to the first blinded data from the pivotal Phase 3 Bria-ABC study: sustained quality of life despite advanced disease and a meaningful TWiST (time without symptoms or toxicity) result. Biomarker tracking continued, with stable or decreasing CAML counts correlating with better progression-free survival in 60% of evaluable patients. The Phase 3 regimen starts the checkpoint inhibitor in Cycle 1 and uses a Bria-IMT formulation without interferon-gamma.